Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

12 trials with published results (67%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

72%

13 trials in Phase 3/4

Results Transparency

86%

12 of 14 completed with results

Key Signals

12 with results100% success

Data Visualizations

Phase Distribution

16Total
P 2 (3)
P 3 (12)
P 4 (1)

Trial Status

Completed14
Withdrawn2
Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05905055Phase 3Completed

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

NCT05733104RecruitingPrimary

A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

NCT05148702Phase 3RecruitingPrimary

EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.

NCT03329092Phase 3CompletedPrimary

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NCT04927312Phase 3CompletedPrimary

Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection

NCT03217136Phase 2CompletedPrimary

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT01265784Phase 2CompletedPrimary

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

NCT03293485Phase 3CompletedPrimary

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

NCT01445678Phase 3CompletedPrimary

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

NCT01147640Phase 2CompletedPrimary

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

NCT02739997Phase 3Completed

Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

NCT01644643Phase 3Completed

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01499290Phase 3CompletedPrimary

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01726023Phase 3CompletedPrimary

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

NCT00157898Phase 4CompletedPrimary

A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)

NCT01602874Phase 3Withdrawn

Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

NCT00929643CompletedPrimary

Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections

NCT00914888Phase 3Withdrawn

Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

Showing all 18 trials

Research Network

Activity Timeline